



INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

IBC Meeting Agenda

Date: Wednesday, November 15, 2023 **Time:** 10:00AM – 12:00PM

Location: Magnuson Health Sciences Building T-269 (enter via main lobby on third floor)
or access by remote dial in: US: +1 206 337 9723; Webinar ID: 998 6682 1484

1. CALL TO ORDER

- Declaration of Quorum

2. REMINDERS

- Public Disclosure & Conflict of Interest Policies

3. APPROVAL OF MINUTES

- October 18, 2023

4. OLD BUSINESS

5. BIOSAFETY OFFICER REPORT

6. INDIVIDUAL PROJECT REVIEWS

Principal Investigator	Title	Project Type
Abkowitz, Janis	<i>The role of FLVCR in hematopoiesis and iron homeostasis</i>	renewal
Bitto, Alessandro	<i>Pharmacological Approaches to Aging and Mitochondrial Disease</i>	renewal
Bryers, James	<i>Injectable Hydrogel Depots for Self-replicating mRNA Vaccine Delivery</i>	renewal
Chamberlain, Jeff	<i>Gene Therapy for Neuromuscular Disorders</i>	change
Greninger, Alex	<i>Quantification and sequencing of viral nucleic acids for surveillance and anti-viral drug discovery</i>	change
Hawkins, Brian	<i>Research, Development, and Manufacturing of Pluripotent Stem Cells and Differentiated Cells for the Treatment of Human Disease</i>	renewal
MacLellan, Robb	<i>Cardiac Development, Growth and Regeneration</i>	renewal
Papayannopoulou, Thalia	<i>Gene therapy for hemoglobinopathies: bone marrow conditioning</i>	change
Qu, Feini	<i>Mechanisms of Complex Musculoskeletal Tissue Regeneration</i>	new
Reniere, Michelle	<i>Redox regulation and virulence in bacterial pathogens</i>	change
Stolla, Massiel	<i>Autophagy and Erythropoiesis</i>	new
Sancak, Yasemin	<i>Role of mitochondrial calcium uptake in health and disease</i>	renewal
Savan, Ram	<i>Gene Regulation of Immune Genes and the Effect on Immune Response</i>	renewal
Soetedjo, Robijanto	<i>Saccade Motor Control</i>	renewal
Woodward, Joshua	<i>Pathogenesis of Listeria monocytogenes</i>	renewal

7. SUBCOMMITTEE REPORTS

Principal Investigator	Title	Project Type
Pamboukian, Salpy	<i>A phase 2, adaptive, double-blinded, placebo controlled, randomized, multicenter trial to evaluate the efficacy, safety and tolerability of intracoronary infusion of NAN-101 in adult subjects with New York Heart Association (NYHA) Class III heart failure and non-ischemic cardiomyopathy</i>	new

8. FOR YOUR INFORMATION

9. ISSUES FROM THE FLOOR & PUBLIC COMMENTS

10. ADJOURNMENT